PDF(Pubmed)
Abstract：
Preeclampsia is a common complication of pregnancy. It is a multi-organ disorder that remains one of the main causes of maternal morbidity and mortality. Additionally, preeclampsia leads to many complications that can occur in the fetus or newborn. Preeclampsia occurs in about 1 in 20 pregnant women. This review focuses on the prediction of preeclampsia in women, using various biomarkers, in particular, a factor combining the use of soluble FMS-like tyrosinokinase-1 (sFlt-1) and placental growth factor (PlGF). A low value of the sFlt-1/PlGF ratio rules out the occurrence of preeclampsia within 4 weeks of the test result, and its high value predicts the occurrence of preeclampsia within even 1 week. The review also highlights other factors, such as pregnancy-associated plasma protein A, placental protein 13, disintegrin and metalloprotease 12, ß-human chorionic gonadotropin, inhibin-A, soluble endoglin, nitric oxide, and growth differentiation factor 15. Biomarker testing offers reliable and cost-effective screening methods for early detection, prognosis, and monitoring of preeclampsia. Early diagnosis in groups of women at high risk for preeclampsia allows for quick intervention, preventing the undesirable effects of preeclampsia. However, further research is needed to validate and optimize the use of biomarkers for more accurate prediction and diagnosis. This article aims to review the role of biomarkers, including the sFlt1/PlGF ratio, in the prognosis and management of preeclampsia.
摘要：
先兆子痫是一种常见的妊娠并发症。它是一种多器官疾病，仍然是孕产妇发病和死亡的主要原因之一。此外,先兆子痫会导致许多可能在胎儿或新生儿中发生的并发症。先兆子痫发生在约1/20的孕妇中。本文就女性子痫前期的预测作一综述,使用各种生物标志物，特别是,结合使用可溶性FMS样酪氨酸激酶-1（sFlt-1）和胎盘生长因子（PlGF）的因子。sFlt-1/PlGF比值的低值排除了在测试结果的4周内先兆子痫的发生。它的高值预测先兆子痫的发生甚至在1周内。审查还强调了其他因素，如妊娠相关血浆蛋白A，胎盘蛋白13，解整合素和金属蛋白酶12，β-人绒毛膜促性腺激素，抑制素A,可溶性内皮糖蛋白，一氧化氮,和生长分化因子15。生物标志物检测为早期检测提供了可靠且具有成本效益的筛选方法，预后,和监测先兆子痫。先兆子痫高危女性群体的早期诊断可以快速干预，预防先兆子痫的不良影响。然而,需要进一步的研究来验证和优化生物标志物的使用,以实现更准确的预测和诊断.本文旨在综述生物标志物的作用,包括sFlt1/PlGF比率，在子痫前期的预后和管理中。
